Eagle Pharmaceuticals, inc. (EGRX)

[Bickema]

Good point which could point to Eagle playing hardball and wishing to remain solo

or Eagle knew they wouldn't receive a fair offer valuing Ryanodex in EHS, which hadn't shown any clinical efficacy at that point, and the rest of their pipeline, which was far from producing revenues.

TEVA's drop today just has me musing on new revenue streams for them

Of course the biggest caveat for me is TEVA's inability to bring a generic epi pen to market may have spooked them from paying a premium for Ryanodex in EHS due to how similarly the two drugs are administered.